结核病治疗开始后IL-1Ra和IP-10血水平的快速下降
Polidy Pean1, Roseline Affi2, Corine Chazalon3
1Immunology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
概括
介素-1受体对抗剂 (IL-1Ra) 的血水平可以快速预测结核病 (TB) 治疗反应. 在开始结核病治疗后一周测量IL-1Ra可能有助于临床医生早期评估治疗的有效性.
科学领域:
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 结核病 (TB) 治疗监测需要快速预测结果的工具.
- 早期评估结核病治疗反应对于患者管理和预防耐药性至关重要.
研究的目的:
- 评估结核病治疗开始后两周内先天性免疫生物标志物的变化是否可以预测治疗反应.
- 评估IL-1Ra,IP-10和CD163的血水平作为结核病治疗疗效的早期指标的有用性.
主要方法:
- 一项前性概念验证研究 (ANRS12394-LILAC-TB) 招募了柬埔寨和科特迪瓦的成年人,这些成年人患有对利芬素敏感的结核病.
- 血生物标志物度 (IL-1Ra,IP-10,CD163) 用酶相关免疫吸收剂测定套件进行测量.
- 用威尔科克森测试对配对数据进行了纵向比较.
主要成果:
- 共有55名患者被录取,其中83%的结核病治疗成功.
- 血IL-1Ra水平在治疗开始后的第一周显著下降,无论艾滋病毒状况如何.
- 血IP-10水平在第1周和第2周也显著下降,尽管在HIV阳性参与者中这种降低不那么明显.
结论:
- 血IL-1Ra水平显示出作为监测结核病治疗反应的早期生物标志物的潜力.
- 在基线和治疗开始后一周内测量IL-1Ra可能有助于临床医生快速评估结核病治疗疗效.
- 这种方法可以促进关于结核病治疗管理的及时临床决策.
相关概念视频
Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Pulmonary Tuberculosis I
240
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
240
Pulmonary Tuberculosis IV
139
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
139
Pulmonary Tuberculosis II
223
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
223
Pulmonary Tuberculosis III
322
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
322
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131


